查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836891

牛皮癬治療市場按治療層級、給藥途徑、分銷管道、最終用戶、疾病嚴重程度和患者年齡層分類 - 全球預測 2025-2032

Psoriasis Therapeutics Market by Therapeutic Class, Route Of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，牛皮癬治療市場將成長至 510.7 億美元，複合年成長率為 10.06%。

主要市場統計數據
基準年2024年 237.1億美元
預計2025年 260.8億美元
預測年份：2032年 510.7億美元
複合年成長率（%） 10.06%

簡潔的基本概述，解釋臨床進展、不斷發展的護理途徑和商業性需求如何重塑牛皮癬治療策略

引言部分透過描述臨床複雜性、不斷發展的治療方法以及不斷變化的醫療服務模式，為深入探索銀屑病治療奠定了基礎。近年來，治療方法創新已從傳統的外用藥物和照光治療擴展到生技藥品和標靶小分子療法，這種多樣化改變了臨床醫生、相關人員和患者群體的期望。隨著關於新作用機制和長期安全性的證據不斷積累，臨床決策管道變得更加精細，要求臨床團隊將生物標記洞察、合併症管理和患者偏好整合到個人化治療方案中。

同時，商業格局正在透過更複雜的分銷安排、基本契約實驗以及旨在解決依從性和療效問題的數位化患者援助計畫來適應這些臨床轉變。付款人和醫療系統越來越需要強力的真實世界證據和健康經濟學原理來支持可及性，而製造商則正在投資於長期療效追蹤和整合護理模式。在此背景下，引言強調了跨研究、監管、報銷和供應鏈職能部門的多學科合作的必要性，以便將科學進步轉化為患者照護的可衡量改進和永續的商業性成果。

臨床創新、監管變革和以患者為中心的護理模式如何推動銀屑病治療開發和商業化的根本轉變

科學突破、監管調整和患者期望的轉變正在推動銀屑病治療領域的變革——這些因素正在改寫臨床研發和藥物開發的規則。免疫學的進步推動了高選擇性生技藥品和精準靶向小分子藥物的開發，重新定義了療效指標和耐受性預期，並迫使臨床醫生重新思考給藥順序、聯合用藥策略和劑量最佳化。監管機構正在透過調整途徑來應對，以支持加速證據生成、有條件核准和上市後數據共享，從而在保持安全監測的同時加快患者用藥。

除了產品層面的創新之外，醫療服務交付和商業模式也正在轉向融合診所管理、送貨上門選項和數位化依從性支援的一體化病人歷程。隨著支付方將支出與可衡量的臨床效益掛鉤，基本契約試點和基於結果的報銷安排正變得越來越普遍。同時，生物相似藥的進入和競爭性定價壓力迫使製造商透過提供服務、患者援助計劃和證據生成來實現差異化。這些綜合轉變迫使相關人員重新評估其臨床通訊協定、合作策略和投資重點，以在快速發展的生態系統中保持競爭力。

評估 2025 年關稅政策的變化如何改變銀屑病治療供應鏈的彈性、籌資策略和臨床物流

2025年宣布的美國關稅的累積影響，為銀屑病治療價值鏈上的企業帶來了成本壓力和戰略考量，影響了供應鏈的韌性、籌資策略和製造地的決策。關稅導致原料、活性藥物成分和某些生技藥品舉措的成本上漲，促使製造商重新評估其供應商的多樣性，並加快近岸生產計劃以降低風險。同時，經銷商和專業藥房正在經歷採購經濟狀況的變化，這要求他們重新協商條款並調整庫存策略，以在控制成本的同時保持服務水準。

這些動態也影響臨床項目物流和臨床實驗藥物供應計劃，臨床實驗藥物採購和跨境運輸將面臨更嚴格的審查，並可能出現延誤。為此，申辦方正在透過多資訊來源採購、策略儲備以及將增強的海關風險模型整合到採購和財務工作流程中來最佳化物流。隨著相關人員與政策制定者的互動，倡導豁免和分階段實施是更廣泛的風險緩解策略的一部分。這些措施有助於維持醫療和臨床實驗室運作的連續性，同時在新的關稅環境下重新調整成本結構和策略重點。

詳細的細分洞察揭示了治療層級、給藥途徑、分銷管道和患者特徵如何決定臨床和商業性方法

關鍵細分洞察揭示了治療層級、給藥途徑、分銷管道、最終用戶、疾病嚴重程度和患者年齡如何影響銀屑病領域的治療選擇、商業策略和服務設計。治療層級的區分——生技藥品、照光治療、小分子藥物和外用藥物——指南臨床定位和付款人對話。生技藥品進一步分為 IL-12/23、IL-17、IL-23 和 TNF 抑制劑，每種抑制劑都表現出不同的功效和安全性，影響治療順序考量。照光治療，如準分子雷射、窄帶 UVB 和 PUVA，是根據患者族群和臨床情況選擇的。小分子藥物，如 JAK 抑制劑和 PDE4 抑制劑，提供影響依從性和監測需求的口服替代品。外用藥物，如Calcineurin抑制劑、皮質類固醇和維生素 D 類似物，是輕度病例和維持策略的核心。

注射、口服和外用藥物的給藥途徑影響患者的偏好和依從性，而注射劑型（如自動注射器、預填充式注射器和管瓶）則影響自我給藥的可行性和臨床工作流程。口服劑型（如膠囊和錠劑）在便利性和監測方面各不相同。醫院藥局、零售藥局和專業藥局（包括送貨上門和診所內配藥的專業子通路）之間的分銷管道細微差別影響著病患的取得和支援計畫的設計。診所、皮膚病中心以及二級和三級醫院的最終用戶環境決定了管理能力和交付管道。將疾病嚴重程度分層為輕度、中度和重度決定了治療強度和護理協調，成人和兒童人群中的患者年齡層決定了不同的安全性、劑量和依從性方法。這些細分結合起來，為產品開發重點、商業化策略和服務產品提供了訊息，使臨床效益與現實世界患者的需求一致。

全球主要地區的不同法規結構、付款人結構和採用模式將如何改變准入策略和營運重點

美洲、歐洲、中東和非洲以及亞太地區的動態呈現出不同的法規環境、付款人結構和應用模式，這些都影響著銀屑病治療的戰略重點。在美洲，衛生技術評估框架和與私人付款人的談判動態決定了打入市場策略，推動了對真實世界證據和患者支持基礎設施的投資，以解決處方集配置和報銷障礙。同時，歐洲、中東和非洲的管理體制和付款人系統各不相同，區域中心和國家報銷政策創造了差異化的採用管道，並需要製定個人化的證據基礎和定價策略。

在亞太地區，生技藥品在某些市場的快速普及、生技藥品產能的不斷提升，以及對價格承受能力和本地法規合規性的關注，促使製造商考慮分階段上市，並與區域經銷商和契約製造製造商合作。跨區域合作和在地化循證驅動的措施日益支持全球產品生命週期，而供應鏈決策（例如區域製造地和分銷管道）則體現了在成本、上市速度和法規合規性之間取得平衡的需求。這些區域差異需要細緻的上市方案和靈活應變的商業模式，既要尊重當地臨床實踐和報銷現實，又要充分利用全球臨床證據和營運規模。

了解主要企業如何平衡產品線創新、策略合作夥伴關係和以患者為中心的商業化以保持競爭優勢

公司層面在乾癬治療領域的行動體現了產品線創新、合作夥伴關係以及差異化患者服務模式的融合，這些因素共同塑造了競爭優勢。主要企業正在優先發展有針對性的生技藥品和小分子項目，並投資於針對特定機制的長期安全性研究，以支持差異化產品說明書和臨床醫生的信心。策略合作，包括與許可、共同開發、合約研究和生產合作夥伴的合作，正在加快臨床開發速度，並擴大複雜生技藥品的生產能力。

主要企業正在透過實施全面的病人參與平台來減少治療啟動和持續性的障礙，這些平台將護理師主導的支持、數位化依從性工具和簡化的報銷協助相結合。一些公司正在與付款人試行基本契約結果的契約，以使定價與實際績效指標保持一致，而其他公司則專注於產品組合合理化和生命週期管理，以擴大治療的相關性。在競爭和政策壓力下，尋求保護淨利率並維持可及性的公司也紛紛投資於製造敏捷性、供應鏈多元化和生物相似藥能力。總體而言，公司策略體現了科學差異化與服務導向商業化的務實結合，旨在滿足未滿足的臨床需求和付款人需求。

為領導者提供實用且可操作的建議，以協調臨床差異化、分銷靈活性和付款人參與度，從而加強市場地位和患者治療效果

為了掌握乾癬治療的長期價值，產業領導者應優先考慮一種整合的方法，將臨床開發、商業模式和供應鏈韌性協調一致。首先，投資差異化機制並累積強力的核准後證據，將有助於臨床推廣和支付方參與，從而在報銷談判中佔據更有利的地位。其次，公司應設計靈活的分銷和給藥途徑，例如家庭給藥方案和方便臨床使用的注射劑，以滿足不斷變化的患者偏好，並減少治療啟動的障礙。

第四，開發一個融合依從性工具、遠端監控和護理支援的數位化病患支援生態系統，將改善現實世界的療效和病患留存率。第五，透過基於價值的試點計畫和透明的療效報告，積極與付款方合作，可以加速處方集的納入和風險分擔安排。最後，領導階層應強調跨職能協作，包括協調醫學事務、HEOR、上市和競爭團隊，將臨床洞察轉化為令人信服的價值提案，並確保營運準備就緒，以保持競爭優勢。

一種透明、多層次的調查方法，結合文獻綜合、專家訪談和三角測量，以產生可靠的、可供決策的發現

調查方法整合了一手和二手研究證據流，對定性專家見解進行三角檢驗，並應用結構化檢驗，以確保分析的嚴謹性和與決策者的相關性。此方法首先全面回顧同儕審查文獻、監管指南、臨床試驗註冊和公開的技術摘要，以建立基礎依證。此外，也對臨床專家、供應鏈經理和市場准入專家進行了半結構化訪談，以補充二手研究，從而捕捉實際營運觀點和新興趨勢，而這些趨勢在已出版的資訊來源中並不常見。

我們運用資料三角測量技術，將這些定性輸入與監管備案文件和產品標籤資訊整合，以驗證關於作用機制、劑量特徵和臨床定位的關鍵聲明。在整個過程中，我們採用了品管，包括與多位獨立專家最後覆核、審查利益衝突，並不斷完善細分框架，以確保清晰度和適用性。我們的調查方法強調透明度、可重複性和相關人員相關性，使其成為臨床、商業和監管領域策略決策和產業計畫的實踐基礎。

結論性綜合強調了整合科學、服務設計和策略敏捷性的必要性，以將治療創新轉化為持久的臨床和商業性成功

總而言之，銀屑病治療領域的特點是科學進步日新月異、交付模式不斷變化以及商業性和監管環境日益複雜，這需要整個生態系統的相關人員制定適應性策略。選擇性生技藥品和標靶小分子藥物的進展正在提高臨床預期，而分銷創新和付款人計劃則要求更完善的證據生成和患者支持機制。供應鏈和政策變化（包括與關稅相關的中斷）凸顯了製造敏捷性和採購多元化對於維持護理和臨床營運連續性的重要性。

未來的成功取決於各機構能否將臨床差異化與切實可行的商業化和供應鏈解決方案相結合，透過透明的療效報告吸引付款方參與，並設計以患者為中心的服務，從而提高依從性和長期療效。在相關人員應對地區差異和競爭壓力的過程中，跨職能協作和積極主動的政策參與仍然至關重要。最終，科學、服務和策略的周密協調將決定哪些機構能夠創新，從而切實改善銀屑病患者的療效。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 長期安全性和有效性的改善增加了 IL-23 抑制劑的採用率
  • 銀屑病生物相似藥的推廣提高了可負擔性和市場競爭力
  • 整合微生物組標靶治療探索腸道-皮膚軸在乾癬治療中的調節作用
  • 人們對局部JAK 抑制劑的興趣日益濃厚，這種抑制劑可提供局部治療，同時減少全身暴露
  • 根據基因組和生物標記見解制定個人化牛皮癬治療方法
  • 使用遠距皮膚病學平台可改善患者獲得專門的牛皮癬治療和監測的機會

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 牛皮癬治療市場（依治療層級）

  • 生技藥品
    • IL-12/23抑制劑
    • IL-17抑制劑
    • IL-23抑制劑
    • TNF抑制劑
  • 照光治療
    • 準分子雷射
    • 窄頻 UVB
    • 普瓦
  • 小分子
    • JAK抑制劑
    • PDE4抑制劑
  • 外用藥物
    • Calcineurin抑制劑
    • 皮質類固醇
    • 維生素D類似物

9. 牛皮癬治療市場（依給藥途徑）

  • 注射
    • 自動注射器
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 藥片
  • 局部的
    • 奶油
    • 凝膠
    • 軟膏

第 10 章 銀屑病治療市場（依分銷管道）

  • 醫院藥房
  • 零售藥局
  • 專業藥房
    • 宅配
    • 院內配藥

第 11 章 牛皮癬治療市場（以最終用戶分類）

  • 診所
  • 皮膚科中心
  • 醫院
    • 次要的
    • 第三

第 12 章 牛皮癬治療市場（依疾病嚴重程度）

  • 溫和的
  • 緩和
  • 嚴重

第13章 銀屑病治療市場（依患者年齡層）

  • 成人
  • 孩子們

第14章 牛皮癬治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 銀屑病治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 銀屑病治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Novartis AG
    • Johnson & Johnson
    • Eli Lilly and Company
    • Pfizer Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Incyte Corporation
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Limited
Product Code: MRR-035AB9C0DA46

The Psoriasis Therapeutics Market is projected to grow by USD 51.07 billion at a CAGR of 10.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 23.71 billion
Estimated Year [2025] USD 26.08 billion
Forecast Year [2032] USD 51.07 billion
CAGR (%) 10.06%

A concise foundational overview explaining how clinical advances, evolving care pathways, and commercial imperatives are reshaping psoriasis therapeutic strategies

The introduction sets the scene for an in-depth exploration of psoriasis therapeutics by framing the clinical complexity, evolving treatment modalities, and shifting care delivery models that define the current landscape. Over recent years, therapeutic innovation has expanded beyond traditional topicals and phototherapy to include a multiplicity of biologic and targeted small molecule approaches, and this diversification has altered stakeholder expectations across clinicians, payers, and patient communities. As evidence accumulates for new mechanisms of action and longer-term safety profiles, clinical decision pathways have become more nuanced, demanding that clinical teams integrate biomarker insights, comorbidity management, and patient preference into individualized regimens.

Concurrently, the commercial environment is adapting to these clinical shifts through more sophisticated distribution arrangements, value-based contracting experiments, and digital patient support programs that address adherence and outcomes. Payers and health systems increasingly require robust real-world evidence and health economic arguments to support access, leading manufacturers to invest in longitudinal outcome tracking and integrated care models. In this context, the introduction underscores the need for multidisciplinary collaboration across research, regulatory, reimbursement, and supply chain functions to translate scientific advances into measurable improvements in patient care and sustainable commercial outcomes.

How clinical innovation, regulatory evolution, and patient-centered care models are jointly driving a fundamental transformation of psoriasis therapy development and commercialization

Transformative shifts within the psoriasis therapeutic landscape are driven by converging scientific breakthroughs, regulatory recalibrations, and changing patient expectations that together rewrite the rules of clinical development and market engagement. Advances in immunology have led to highly selective biologics and precision-targeted small molecules that redefine efficacy benchmarks and tolerability expectations, prompting clinicians to reconsider sequencing, combination strategies, and dose optimization. Regulatory agencies have responded with pathway adjustments that accommodate accelerated evidence generation, conditional approvals, and collaborative post-marketing data commitments, which in turn accelerate patient access while maintaining safety oversight.

Beyond product-level innovation, care delivery and commercial models are shifting toward integrated patient journeys that blend clinic-based administration, home delivery options, and digital adherence supports. Value-based contracting pilots and outcomes-based reimbursement arrangements are becoming more prevalent as payers align spending with measurable clinical benefits. Meanwhile, biosimilar entry and competitive price dynamics are prompting manufacturers to differentiate through service offerings, patient support programs, and evidence generation. These combined shifts compel stakeholders to re-evaluate clinical protocols, partnership strategies, and investment priorities to remain competitive in a rapidly evolving ecosystem.

Assessing how tariff policy shifts in 2025 have reshaped supply chain resilience, sourcing strategies, and clinical logistics across psoriasis therapeutics

The cumulative impact of United States tariffs announced in 2025 has introduced discrete cost pressures and strategic considerations for organizations operating across the psoriasis therapeutic value chain, affecting supply chain resilience, sourcing strategies, and manufacturing footprint decisions. Tariff-induced increases in the cost of raw materials, active pharmaceutical ingredients, and certain biologics components have prompted manufacturers to re-assess supplier diversity and to accelerate near-shore manufacturing initiatives to mitigate exposure. In parallel, distributors and specialty pharmacies have experienced shifts in procurement economics that require renegotiation of commercial terms and reconfiguration of inventory strategies to preserve service levels while containing costs.

These dynamics have also influenced clinical program logistics and trial supply planning, as investigational material sourcing and cross-border shipments have become subject to additional scrutiny and potential delays. In response, sponsors are optimizing logistics through multi-sourced procurement, strategic stockpiling, and enhanced tariff-risk modeling embedded in procurement and finance workflows. Regulatory and policy dialogue remains a crucial variable; as stakeholders engage with policymakers, advocacy for exemptions or phased approaches has become part of broader risk mitigation strategies. Together, these measures have helped organizations preserve continuity of care and clinical trial operations while recalibrating cost structures and strategic priorities under the new tariff environment.

Detailed segmentation insights revealing how therapeutic class, administration route, distribution pathways, and patient characteristics determine clinical and commercial approaches

Key segmentation insights reveal how therapeutic class, route of administration, distribution channel, end user, disease severity, and patient age shape treatment selection, commercial strategy, and service design across the psoriasis space. Therapeutic class differentiation between biologics, phototherapy, small molecules, and topicals guides clinical positioning and payer conversations, with biologics further divided across IL-12/23, IL-17, IL-23, and TNF inhibitors each exhibiting distinct efficacy and safety attributes that influence sequencing considerations. Phototherapy modalities such as excimer laser, narrowband UVB, and PUVA serve defined patient cohorts and clinical contexts, while small molecule options like JAK inhibitors and PDE4 inhibitors offer oral alternatives that affect adherence and monitoring needs. Topical agents, including calcineurin inhibitors, corticosteroids, and vitamin D analogues, remain central for milder disease and for maintenance strategies.

Route of administration considerations among injectable, oral, and topical options influence patient preference and adherence, with injectable delivery subtypes such as auto-injectors, pre-filled syringes, and vials affecting self-administration feasibility and clinic workflows. Oral formulations across capsule and tablet forms alter convenience and monitoring profiles. Distribution channel nuances across hospital pharmacy, retail pharmacy, and specialty pharmacy, including specialty subchannels of home delivery and in-clinic dispensing, shape patient access and support program design. End user context across clinics, dermatology centers, and hospitals-spanning secondary and tertiary facilities-determines administration capabilities and referral pathways. Disease severity stratification into mild, moderate, and severe directs therapeutic intensity and care coordination, while patient age groups of adult and pediatric populations require differentiated safety, dosing, and adherence approaches. Collectively, these segmentation lenses inform product development priorities, commercialization tactics, and service offerings that align clinical benefit with real-world patient needs.

How distinct regulatory frameworks, payer structures, and adoption patterns across key global regions reshape access strategies and operational priorities

Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific present distinct regulatory environments, payer architectures, and adoption patterns that influence strategic priorities for psoriasis therapeutics. In the Americas, health technology assessment frameworks and private payer negotiation dynamics shape market access strategies, driving investment in real-world evidence and patient support infrastructure to address formulary placement and reimbursement hurdles. Meanwhile, Europe, Middle East & Africa comprises diverse regulatory regimes and heterogeneous payer systems where regional centers of excellence and national reimbursement policies create differentiated uptake paths and require tailored evidence dossiers and pricing strategies.

Asia-Pacific features rapid adoption in selected markets, growing biologics manufacturing capacity, and a strong emphasis on affordability and local regulatory alignment, prompting manufacturers to consider tiered launch approaches and partnerships with regional distributors and contract manufacturers. Cross-region collaborations and localized evidence generation efforts increasingly support global product lifecycles, and supply chain decisions such as regional manufacturing hubs and distribution pathways reflect the need to balance cost, speed-to-market, and regulatory compliance. These regional distinctions require nuanced market entry playbooks and adaptive commercial models that respect local clinical practices and reimbursement realities while leveraging global clinical evidence and operational scale.

Insights into how leading companies balance pipeline innovation, strategic alliances, and patient-centric commercialization to sustain competitive advantage

Company-level behavior in psoriasis therapeutics reflects a blend of pipeline innovation, collaborative partnerships, and differentiated patient service models that together shape competitive positioning. Leading organizations have prioritized targeted biologic and small molecule programs, investing in mechanistic precision and long-term safety studies to support differentiated label claims and clinician confidence. Strategic collaborations, including licensing, co-development, and alliances with contract research and manufacturing partners, have accelerated time-to-clinic and expanded capacity for complex biologic production.

Commercially, companies are increasingly deploying holistic patient engagement platforms that combine nurse-led support, digital adherence tools, and streamlined reimbursement assistance to reduce barriers to initiation and persistence. Several firms have embraced outcomes-based contracting pilots with payers to align pricing with real-world performance metrics, while others focus on portfolio rationalization and lifecycle management to extend therapeutic relevance. Manufacturing agility, supply chain diversification, and investments in biosimilar readiness represent additional themes as companies seek to protect margins and maintain access in the face of competitive and policy pressures. Overall, corporate strategies exhibit a pragmatic mix of scientific differentiation and service-oriented commercialization to address both clinical unmet needs and payer demands.

Practical, actionable recommendations for leaders to align clinical differentiation, distribution flexibility, and payer engagement to strengthen market position and patient outcomes

Industry leaders should prioritize an integrated approach that aligns clinical development, commercial models, and supply chain resilience to capture long-term value in psoriasis therapeutics. First, investing in mechanistic differentiation and robust post-approval evidence generation will support both clinical uptake and payer engagement, enabling stronger positioning during reimbursement negotiations. Second, companies should design flexible distribution and administration pathways that include home-based delivery options and clinic-friendly injectables to meet evolving patient preferences and reduce barriers to treatment initiation.

Third, fostering partnerships with regional manufacturers and logistics providers can mitigate tariff and geopolitical risk while improving supply continuity, and fourth, developing digital patient support ecosystems that combine adherence tools, remote monitoring, and nursing support will enhance real-world outcomes and retention. Fifth, engaging proactively with payers through value-based pilots and transparent outcomes reporting can accelerate formulary inclusion and shared-risk arrangements. Finally, leadership should emphasize cross-functional alignment-linking medical affairs, HEOR, market access, and commercial teams-to translate clinical insights into compelling value propositions and operational readiness that sustain competitive performance.

A transparent, multi-layered research methodology combining literature synthesis, expert interviews, and triangulation to produce robust, decision-ready insights

The research methodology synthesizes primary and secondary evidence streams, triangulates qualitative expert insights, and applies structured validation to ensure analytical rigor and relevance for decision-makers. The approach began with a comprehensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, and publicly available technical briefings to establish a foundational evidence base. This secondary research was complemented by semi-structured interviews with clinical specialists, supply chain managers, and market access professionals to capture practical operational perspectives and emergent trends that are not always visible in published sources.

Data triangulation techniques integrated these qualitative inputs with regulatory filings and product labeling information to validate key claims around mechanisms of action, administration characteristics, and clinical positioning. Throughout the process, quality controls included cross-checks with multiple independent experts, scrutiny for conflicts of interest, and iterative refinement of segmentation frameworks to ensure clarity and applicability. The methodology emphasizes transparency, reproducibility, and stakeholder relevance, enabling the research to serve as a pragmatic foundation for strategic decision-making and operational planning across clinical, commercial, and regulatory domains.

A conclusive synthesis highlighting the necessity of integrated science, service design, and strategic agility to convert therapeutic innovation into enduring clinical and commercial success

In conclusion, the psoriasis therapeutics landscape is characterized by rapid scientific progress, changing delivery models, and an increasingly complex commercial and regulatory environment that together require adaptive strategies from stakeholders across the ecosystem. Advances in selective biologics and targeted small molecules have raised clinical expectations, while distribution innovations and payer experimentation demand more sophisticated evidence generation and patient support mechanisms. Supply chain and policy shifts, including tariff-related disruptions, have underscored the importance of manufacturing agility and procurement diversification to sustain continuity of care and clinical operations.

Looking ahead, success will hinge on the ability of organizations to integrate clinical differentiation with pragmatic commercialization and supply chain solutions, to engage payers through transparent outcomes reporting, and to design patient-centered services that improve adherence and long-term outcomes. Cross-functional collaboration and proactive policy engagement will remain essential as stakeholders navigate regional variability and competitive pressures. Ultimately, thoughtful alignment of science, service, and strategy will determine which organizations translate innovation into meaningful improvements for patients living with psoriasis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of IL-23 inhibitors driven by improved long-term safety and efficacy profiles
  • 5.2. Expansion of biosimilars for psoriasis leading to increased affordability and market competition
  • 5.3. Integration of microbiome-targeted therapies exploring gut-skin axis modulation in psoriasis management
  • 5.4. Growing interest in topical JAK inhibitors offering localized treatment with reduced systemic exposure
  • 5.5. Development of personalized psoriatic treatment regimens based on genomic and biomarker-driven insights
  • 5.6. Use of teledermatology platforms enhancing patient access to specialized psoriasis care and monitoring

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Therapeutics Market, by Therapeutic Class

  • 8.1. Biologics
    • 8.1.1. IL-12/23 Inhibitors
    • 8.1.2. IL-17 Inhibitors
    • 8.1.3. IL-23 Inhibitors
    • 8.1.4. TNF Inhibitors
  • 8.2. Phototherapy
    • 8.2.1. Excimer Laser
    • 8.2.2. Narrowband Uvb
    • 8.2.3. Puva
  • 8.3. Small Molecules
    • 8.3.1. JAK Inhibitors
    • 8.3.2. PDE4 Inhibitors
  • 8.4. Topicals
    • 8.4.1. Calcineurin Inhibitors
    • 8.4.2. Corticosteroids
    • 8.4.3. Vitamin D Analogues

9. Psoriasis Therapeutics Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Auto-Injector
    • 9.1.2. Pre-Filled Syringe
    • 9.1.3. Vial
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet
  • 9.3. Topical
    • 9.3.1. Cream
    • 9.3.2. Gel
    • 9.3.3. Ointment

10. Psoriasis Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Retail Pharmacy
  • 10.3. Specialty Pharmacy
    • 10.3.1. Home Delivery
    • 10.3.2. In-Clinic Dispensing

11. Psoriasis Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Dermatology Centers
  • 11.3. Hospitals
    • 11.3.1. Secondary
    • 11.3.2. Tertiary

12. Psoriasis Therapeutics Market, by Disease Severity

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Psoriasis Therapeutics Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Pediatric

14. Psoriasis Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Psoriasis Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Psoriasis Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Novartis AG
    • 17.3.3. Johnson & Johnson
    • 17.3.4. Eli Lilly and Company
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Amgen Inc.
    • 17.3.7. Bristol-Myers Squibb Company
    • 17.3.8. Incyte Corporation
    • 17.3.9. Merck & Co., Inc.
    • 17.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE